<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04891237</url>
  </required_header>
  <id_info>
    <org_study_id>DMV02-SIT-027</org_study_id>
    <nct_id>NCT04891237</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen</brief_title>
  <official_title>A Randomized, Double-Blinded, Placebo-Controlled, Prospective, Multicenter CT to Evaluate Efficacy and Safety of Subcutaneous Immunotherapy in Subjects With Rhinitis With/Without Mild to Moderate Asthma Sensitized to Olive and Grass Pollen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inmunotek S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inmunotek S.L.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial of&#xD;
      efficacy and safety with subcutaneous immunotherapy in patients with mild to moderate&#xD;
      rhinitis / rhinoconjunctivitis with or without mild to moderate asthma sensitized to grasses&#xD;
      and olive&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double blind, multicenter, parallel, placebo controlled study. It includes 180 subjects&#xD;
      sensitised to olea and grass pollen with mild to moderate rhinitis / rhinoconjunctivitis with&#xD;
      or without mild to moderate asthma, from 12 to 65 years of age. Medication treatment during 1&#xD;
      year. The main outcome: CSMS&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 14, 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, placebo-controlled, multicentre, parallel-group study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>During the trial, both the investigator and the included subjects will be unaware of the treatment each subject is receiving.&#xD;
The person in charge of data analysis will also not know the treatment assigned to each subject until the database has been closed.&#xD;
So that neither the subject nor the investigator knows what treatment each subject is receiving, all the trial medication is identical in terms of outer packaging and appearance.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>CSMS: Combined Symptoms and Medication Score</measure>
    <time_frame>12 months</time_frame>
    <description>Overall score of symptoms and medication throughout the trial. The minimum score is cero and maximum six, per day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Medication-free days</measure>
    <time_frame>12 months</time_frame>
    <description>Number of days that the subjects need no medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom-free days</measure>
    <time_frame>12 months</time_frame>
    <description>Number of days that the subjects have no symptom</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthmatic exacerbations</measure>
    <time_frame>12 months</time_frame>
    <description>Time elapsed until the first appearance of asthmatic exacerbations,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale (VAS)</measure>
    <time_frame>12 months</time_frame>
    <description>Visual Analogue Scale in which the subject has to indicate in a straight line of 10cm how he/she feels regarding to his allergy symptoms. Being left side very bad and right side very well</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life rhinitis test</measure>
    <time_frame>12 months</time_frame>
    <description>Quality of life rhinitis test (ESPRINT-15)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life asthma test</measure>
    <time_frame>12 months</time_frame>
    <description>Control of asthma by Asthma Control Quality questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health resources</measure>
    <time_frame>12 months</time_frame>
    <description>For each patient, the number of times that due to allergy symptoms has done the following will be counted:&#xD;
Have visited the GP, Have made an unscheduled visit to the specialist, Has gone to the emergency room, Has been hospitalized, Have needed to contact the doctor by phone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological parameters</measure>
    <time_frame>12 months</time_frame>
    <description>Analyses of total and specific IgE, specific Ig G4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Security parameters</measure>
    <time_frame>12 months</time_frame>
    <description>Global rate and severity of AE per administration and per subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Reactions</measure>
    <time_frame>12 months</time_frame>
    <description>Local and systemic reactions and any medication administered for the treatment of AR</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Rhinitis, Allergic</condition>
  <condition>Rhinoconjunctivitis</condition>
  <condition>Asthma, Allergic</condition>
  <arm_group>
    <arm_group_label>10,000 MG01 + 10,000 T517</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10,000 TU/mL of MG01 + 10,000 TU/mL of T517 of subcutaneous immunotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30,000 MG01 + 10,000 T517</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30,000 TU/mL of MG01 + 10,000 TU/mL of T517 of subcutaneous immunotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo subcutaneous</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The same solution and presentation as the active treatment, but without active ingredients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>10,000 MG01 + 10,000 T517</intervention_name>
    <description>Purified and polymerized with glutaraldehyde allergen extract, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and Olea (Olea europaea), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections</description>
    <arm_group_label>10,000 MG01 + 10,000 T517</arm_group_label>
    <other_name>Grasses and olea 10,000</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>30,000 MG01 + 10,000 T517</intervention_name>
    <description>Purified and polymerized with glutaraldehyde allergen extract, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and Olea (Olea europaea), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections</description>
    <arm_group_label>30,000 MG01 + 10,000 T517</arm_group_label>
    <other_name>Grasses and olea</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The same solution and presentation as the active treatment, but without active ingredients</description>
    <arm_group_label>Placebo subcutaneous</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject who has signed the informed consent.&#xD;
&#xD;
          2. Subjects of both sexes aged between 12 and 65 years.&#xD;
&#xD;
          3. Subjects with confirmed clinical history of inhalational allergy (rhinitis and / or&#xD;
             moderate-severe intermittent or persistent rhinoconjunctivitis according to the ARIA&#xD;
             classification with or without intermittent or persistent controlled mild-moderate&#xD;
             asthma according to the GEMA 5.0 classification caused by grass and olive allergy. The&#xD;
             diagnosis of asthma will be valid from 12 months prior to signing the informed consent&#xD;
&#xD;
          4. Subjects with a positive prick test (higher papule diameter ≥ 5 mm) to a standardized&#xD;
             extract of pollen from grasses (Phleum pratense, Holcus lanatus, Dactylis glomerata,&#xD;
             Poa pratensis, Festuca elatior, Lolium perenne), or one of the components of the&#xD;
             mixture and an olive extract, made within 12 months prior to signing the informed&#xD;
             consent.&#xD;
&#xD;
          5. Specific IgE (CAP or Immulite) against a mixture of grasses or against one of the&#xD;
             components of the mixture of grasses, preferably Phleum pratense and olive or one of&#xD;
             the molecular components of allergenic sources with a value &gt; 3,5 KU / L, determined&#xD;
             within the 12 months prior to signing the informed consent.&#xD;
&#xD;
          6. Women of childbearing age (from menarche) should submit a urine pregnancy test with a&#xD;
             negative result at the time of joining the trial.&#xD;
&#xD;
          7. Women of childbearing potential, and men participating in the trial, should commit to&#xD;
             using an appropriate method of contraception. Medically acceptable methods of&#xD;
             contraception are intrauterine devices placed at least 3 months in advance, surgical&#xD;
             sterilization (for example, tubal ligation), barrier methods, or the use of oral&#xD;
             contraceptives.&#xD;
&#xD;
          8. Subjects capable of complying with the dosage regimen.&#xD;
&#xD;
          9. Subjects who have a smartphone to record symptoms and medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects polysensitized to other aeroallergens with the exception of epithelia with&#xD;
             exposure and occasional symptoms and non-seasonal pollens with grasses and olive&#xD;
&#xD;
          2. Subjects who have received prior immunotherapy in the preceding 5 years to any&#xD;
             aeroallergens.&#xD;
&#xD;
          3. Subjects in which immunotherapy may be subject to an absolute general contraindication&#xD;
             according to the criteria of the Immunotherapy Committee of the Spanish Society of&#xD;
             Allergy and Clinical Immunology and the European Allergy and Clinical Immunology&#xD;
             Immunotherapy Subcommittee.&#xD;
&#xD;
          4. Subjects with severe or uncontrolled persistent asthma, with an FEV1 &lt;70% with respect&#xD;
             to the reference value despite adequate pharmacological treatment at the time of&#xD;
             inclusion in the trial. Likewise, subjects with intermittent or persistent rhinitis /&#xD;
             rhinoconjunctivitis with severe symptoms in which the suspension of oral or systemic&#xD;
             antihistamine treatment is contraindicated.&#xD;
&#xD;
          5. Subjects who have previously presented a serious secondary reaction during the&#xD;
             performance of diagnostic skin tests using the prick test.&#xD;
&#xD;
          6. Subjects under treatment with ß-blockers.&#xD;
&#xD;
          7. Clinically unstable subjects at the time of enrollment in the trial (acute asthma&#xD;
             exacerbation, respiratory infection, feverish process, acute urticaria, etc.).&#xD;
&#xD;
          8. Subjects with active chronic urticaria, severe dermographism, severe atopic&#xD;
             dermatitis, sunburns, active psoriasis with lesions in areas where skin tests will be&#xD;
             performed, or a history of hereditary angioedema.&#xD;
&#xD;
          9. Subjects who have any pathology in which the administration of adrenaline is&#xD;
             contraindicated (hyperthyroidism, HT, heart disease, etc.).&#xD;
&#xD;
         10. Subjects with some other disease not related to moderate rhinoconjunctivitis or&#xD;
             asthma, but of potential severity and that may interfere with treatment and follow-up&#xD;
             (epilepsy, psychomotor disorder, uncontrolled diabetes, malformations, multiple&#xD;
             operations, kidney disease,).&#xD;
&#xD;
         11. Subjects with autoimmune disease (thyroiditis, lupus, etc.), tumor diseases or with a&#xD;
             diagnosis of immunodeficiencies.&#xD;
&#xD;
         12. Subject whose condition prevents him / her from offering cooperation and who has&#xD;
             severe psychiatric disorders.&#xD;
&#xD;
         13. Subjects with a known allergy to other investigational drug components other than the&#xD;
             allergen.&#xD;
&#xD;
         14. Subjects with diseases of the lower respiratory tract other than asthma such as&#xD;
             emphysema or bronchiectasis.&#xD;
&#xD;
         15. Subjects who are direct relatives of the researchers.&#xD;
&#xD;
         16. Pregnant or lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ANGEL MORAL</last_name>
    <role>Study Chair</role>
    <affiliation>Private Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Miguel Casanovas</last_name>
    <phone>912908942</phone>
    <phone_ext>0034</phone_ext>
    <email>mcasanovas@inmunotek.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raquel Caballero</last_name>
    <phone>607600638</phone>
    <phone_ext>34</phone_ext>
    <email>rcaballero@inmunotek.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Private Centre</name>
      <address>
        <city>Sant Cugat Del Vallès</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Óscar Asensio de la Cruz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedt de Tarancón</name>
      <address>
        <city>Tarancon</city>
        <state>Cuenca</state>
        <zip>16400</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>ANTONIO MORENO FERNÁNDEZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Torrejón</name>
      <address>
        <city>Torrejón De Ardoz</city>
        <state>Madrid</state>
        <zip>28850</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Armando Bueso Fernández, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Privada</name>
      <address>
        <city>Sevila</city>
        <state>Sevilla</state>
        <zip>41020</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>ALBERTO CASO VÁZQUEZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Privada</name>
      <address>
        <city>Albacete</city>
        <zip>02003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Miguel Torrecillas Toro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Dermatologica Y Alergia</name>
      <address>
        <city>Badajoz</city>
        <zip>06001</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Irán Sánchez Ramos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dexeus</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elena Botey Faraudo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Quironsalud Córdoba</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ignacio García Nuñez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clínico San Cecilio</name>
      <address>
        <city>Granada</city>
        <zip>18016</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>José Fernando Florido López, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>María José Rojas Vilchez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>María Ángeles Lara Jiménez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carolina Mérida Fernández, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Enrique Martín Casañez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Jaén</name>
      <address>
        <city>Jaén</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Blanca Saenz de San Pedro Morera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen Laura Cañada Porta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manuel Alcántara Villar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan Luis Anguita Carazo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>María Antonia Navarrete del Pimo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sara Anaya Anaya, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Santa María</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eva Alcoceba Borrás, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Privada</name>
      <address>
        <city>Madrid</city>
        <zip>28001</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Silvia De Miguel Comes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Subiza</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Javier Subiza Garrido-Lestache, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Concepción Barjau Buj, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cap José Marvá</name>
      <address>
        <city>Madrid</city>
        <zip>28020</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Margarita Tomás Pérez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Javier Contreras Porta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan Alberto Luna Porta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Rey Juan Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28933</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pilar Gajate Fernández, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Privada</name>
      <address>
        <city>Palencia</city>
        <zip>34001</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Izaskun Leanizbarrutia De Bizkarralegorra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Dr. Martín</name>
      <address>
        <city>Sevilla</city>
        <zip>41005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>AGUSTÍN VELLOSO FEIJÓO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Joaquín Quiralte Enriquez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Viamed Santa Ángela de La Cruz</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>MÓNICA DONADO NORTES, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hm Imi Toledo</name>
      <address>
        <city>Toledo</city>
        <zip>45005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ángel Moral de Gregorio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Subiza J, Feliú A, Subiza JL, Uhlig J, Fernández-Caldas E. Cluster immunotherapy with a glutaraldehyde-modified mixture of grasses results in an improvement in specific nasal provocation tests in less than 2.5 months of treatment. Clin Exp Allergy. 2008 Jun;38(6):987-94. doi: 10.1111/j.1365-2222.2008.02995.x. Epub 2008 Apr 25.</citation>
    <PMID>18445082</PMID>
  </reference>
  <reference>
    <citation>Klimek L, Uhlig J, Mösges R, Rettig K, Pfaar O. A high polymerized grass pollen extract is efficacious and safe in a randomized double-blind, placebo-controlled study using a novel up-dosing cluster-protocol. Allergy. 2014 Dec;69(12):1629-38. doi: 10.1111/all.12513. Epub 2014 Oct 6.</citation>
    <PMID>25130503</PMID>
  </reference>
  <reference>
    <citation>Guzmán-Fulgencio M, Caballero R, Lara B, Mena M, Tejera M, Sastre A, Subiza JL, Fernández-Caldas E, Casanovas M. Safety of immunotherapy with glutaraldehyde modified allergen extracts in children and adults. Allergol Immunopathol (Madr). 2017 Mar - Apr;45(2):198-207. doi: 10.1016/j.aller.2016.08.008. Epub 2016 Dec 7.</citation>
    <PMID>27939406</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 30, 2021</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2021</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rhinitis/ Rhinoconjunctivitis</keyword>
  <keyword>Mild to moderate asthma</keyword>
  <keyword>Allergy</keyword>
  <keyword>Grasses</keyword>
  <keyword>Olea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

